Business Description
Disruptive Pharma AB
SIC : 7372
ISIN : SE0021181559
Description
Disruptive Pharma AB is a Swedish pharmaceutical technology company that develops and commercializes Formulite, a patented drug delivery platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability, and other properties of poorly soluble pharmaceutical compounds. The company operates a business model centered on contract development, research partnerships, and licensing arrangements with pharmaceutical and biotechnology companies, which use Formulite to optimize drug candidates and reformulate existing products. Rather than developing and marketing its own medicines, Disruptive Pharma generates revenue through collaboration and licensing fees, milestone payments, and royalties tied to partners' development and commercialization progress. Its activities span early-stage formulation work through technology transfer to partners, with its primary market being the international pharmaceutical and biotechnology industry. The company is based in Sweden.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.69 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.06 | |||||
Quick Ratio | 3.06 | |||||
Cash Ratio | 2.51 | |||||
Days Sales Outstanding | 108.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2291.68 | |||||
Net Margin % | -2272.98 | |||||
EBITDA Margin % | -2239.34 | |||||
ROE % | -161.81 | |||||
ROA % | -122.98 | |||||
ROIC % | -850.53 | |||||
ROC (Joel Greenblatt) % | -3114.22 | |||||
ROCE % | -161.78 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 60.5 | |||||
PB Ratio | 7.91 | |||||
Price-to-Tangible-Book | 8.07 | |||||
EV-to-EBIT | -2.5 | |||||
EV-to-EBITDA | -2.54 | |||||
EV-to-Revenue | 56.87 | |||||
EV-to-FCF | -2.64 | |||||
| Price-to-Net-Current-Asset-Value | 8.64 | |||||
| Price-to-Net-Cash | 12.1 | |||||
Earnings Yield (Greenblatt) % | -39.93 | |||||
FCF Yield % | -38.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Disruptive Pharma AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -2.634 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 39.43 | ||
| 14-Day ATR (kr) | 0.188352 | ||
| 20-Day SMA (kr) | 1.3305 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (kr) | 1.062 - 1.8 | ||
| Shares Outstanding (Mil) | 44.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Disruptive Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Disruptive Pharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-18 | In 149 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 52 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | -- | ||
| General meeting for 2026 | 2026-05-28 | -- | ||
| First quarter earnings results for 2026 | 2026-05-11 | -- | ||
| Annual report for 2025 | 2026-04-21 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-02-20 | -- | ||
| Third quarter earnings results for 2025 | 2025-11-13 | -- | ||
| Second quarter earnings results for 2025 | 2025-08-21 | -- | ||
| General meeting for 2025 | 2025-05-15 10:00 | -- |
Show
Entries
Disruptive Pharma AB Frequently Asked Questions
What is Disruptive Pharma AB(OSTO:DPHA)'s stock price today?
The current price of OSTO:DPHA is kr1.21. The 52 week high of OSTO:DPHA is kr1.80 and 52 week low is kr1.06.
When is next earnings date of Disruptive Pharma AB(OSTO:DPHA)?
The next earnings date of Disruptive Pharma AB(OSTO:DPHA) is 2026-11-13.
Does Disruptive Pharma AB(OSTO:DPHA) pay dividends? If so, how much?
Disruptive Pharma AB(OSTO:DPHA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers